Ginkgo Bioworks is up 1.7% or 2c per share to $1.24 per share, just shy of its intraday high on Tuesday afternoon, after announcing that German start-up Cambrium and Ginkgo Bioworks successfully completed their collaboration. Through the partnership, Cambrium and Ginkgo combined their capabilities to enable the rapid and cost-effective design of high performing, industrially relevant microbes for protein production.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DNA:
- Ginkgo Bioworks, Cambrium complete protein production collaboration
- Ginkgo Bioworks, Syngenta Seeds announce collaboration
- Ginkgo Bioworks, INRB of Congo enter MOU
- Ginkgo Bioworks and WARF partner for GD2 CAR T-Cell therapies
- Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio’s AAV Capsid Discovery and Engineering Platform Assets